Stocks › FATE

FATE THERAPEUTICS INC

FATE·Nasdaq·United States United States·USD
$0.92
-0.09 (-9.01%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
FATE
FATE THERAPEUTICS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
FATES&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of FATE by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY FATEFATE THERAPEUTICS INC · Stock Sale
$1,001 - $15,000
Feb 24, 2023 Jan 31, 2023 Filing ↗

Whale Activity

Position changes in FATE reported for 2026-09-30 by 171 institutional filers
Increased: 32New: 17Held: 41Decreased: 50Closed: 29No prior filing: 2
  • Increased32
  • New17
  • Held41
  • Decreased50
  • Closed29
  • No prior filing2
FilerSharesValueChange
Redmile Group, LLC12.9M$30.5Mheld
BlackRock, Inc.7.1M$16.8Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC5.0M$11.8Mincreased
ACADIAN ASSET MANAGEMENT LLC4.8M$11.3Mincreased
VANGUARD CAPITAL MANAGEMENT LLC4.5M$10.7Mincreased
TWO SIGMA INVESTMENTS, LP3.9M$9.3Mincreased
JOHNSON & JOHNSON3.4M$8.0Mheld
RENAISSANCE TECHNOLOGIES LLC2.4M$5.6Mdecreased
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP2.4M$5.6Mincreased
MILLENNIUM MANAGEMENT LLC2.2M$5.1Mdecreased
GOLDMAN SACHS GROUP INC2.1M$4.9Mincreased
Qube Research & Technologies Ltd1.7M$3.9Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by FATE insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: -20.3K2025 Q12025 Q2: 02025 Q22025 Q3: -23.5K2025 Q32025 Q4: 02025 Q42026 Q1: -15.8K2026 Q12026 Q2: -54.5K2026 Q22026 Q3: -82.7K2026 Q32026 Q4: -6,5822026 Q4

Recent Insider Transactions

641 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Adawi KamalChief Financial Officer Sale −6,582 $2.05 $14K Nov 3, 2026 Form 4 ↗
TAHL CINDYSee Remarks Sale −38.8K $2.46 $95K Aug 4, 2026 Form 4 ↗
Valamehr BahramPresident and CEO · Director Sale −43.9K $2.46 $108K Aug 4, 2026 Form 4 ↗
TAHL CINDYSee Remarks Sale −25.6K $1.88 $48K May 20, 2026 Form 4 ↗
Valamehr BahramPresident and CEO · Director Sale −28.9K $1.88 $54K May 20, 2026 Form 4 ↗
TAHL CINDYSee Remarks Option exercise +44.4K $1.05 $47K May 6, 2026 Form 4 ↗
TAHL CINDYSee Remarks Option exercise +122.2K $1.32 $161K May 6, 2026 Form 4 ↗
EPSTEIN ROBERT SDirector Option exercise +25.0K $1.69 $42K May 5, 2026 Form 4 ↗
RASTETTER WILLIAM HDirector Option exercise +25.0K $1.69 $42K May 5, 2026 Form 4 ↗
Green JeremyDirector · 10% owner Other +9.0M $0.00 $0 Apr 20, 2026 Form 4 ↗
Green JeremyDirector · 10% owner Other −9.0M $0.00 $0 Apr 20, 2026 Form 4 ↗
TAHL CINDYSee Remarks Grant / award +100.0K $0.00 $0 Jan 15, 2026 Form 4 ↗
Adawi KamalChief Financial Officer Grant / award +25.0K $0.00 $0 Jan 15, 2026 Form 4 ↗
Valamehr BahramPresident and CEO · Director Grant / award +335.0K $0.00 $0 Jan 15, 2026 Form 4 ↗
TAHL CINDYSee Remarks Sale −10.6K $1.06 $11K Jan 9, 2026 Form 4 ↗
Valamehr BahramPresident and CEO · Director Sale −5,190 $1.07 $6K Jan 9, 2026 Form 4 ↗
Adawi KamalChief Financial Officer Grant / award +75.0K $0.00 $0 Oct 20, 2025 Form 4 ↗
TAHL CINDYSee Remarks Sale −9,037 $1.06 $10K Aug 4, 2025 Form 4 ↗
Valamehr BahramPresident and CEO · Director Sale −14.5K $1.06 $15K Aug 4, 2025 Form 4 ↗
TAHL CINDYSee Remarks Grant / award +70.0K $0.00 $0 Jan 15, 2025 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding FATE · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.2M$8.6M0.00%Jun 30, 2026
VANGUARD STRATEGIC EQUITY FUND
VANGUARD HORIZON FUNDS
3.0M$8.0M0.07%Jun 30, 2026
BlackRock Advantage Small Cap Core Fund
BlackRock Funds
1.6M$3.8M0.07%Aug 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.1M$3.1M0.00%Jun 30, 2026
BRUCE FUND
Bruce Fund, Inc.
989.2K$2.7M0.71%Jun 30, 2026
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND
VANGUARD HORIZON FUNDS
786.8K$2.1M0.07%Jun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.629.8K$1.7M0.02%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
559.3K$1.6M0.01%May 31, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.1M$1.3M0.00%Apr 30, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
513.8K$1.2M0.00%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list FATE's shares (CUSIP 31189P102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Redmile Capital Offshore II Master Fund, Ltd.SCHEDULE 13D/A · activist (13D) · 6.4M shares5.0%
    Nov 9, 2026 · ↗
  • RedCo II Offshore SPV LLCSCHEDULE 13D/A · activist (13D) · 10.1M shares8.1%
    Nov 9, 2026 · ↗
  • Jeremy C. GreenSCHEDULE 13D/A · activist (13D) · 19.2M shares15.0%
    Nov 9, 2026 · ↗
  • Redmile Group, LLCSCHEDULE 13D/A · activist (13D) · 19.2M shares15.0%
    Nov 9, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 2.2M shares1.9%
    Jul 8, 2026 · ↗
  • GOLDMAN SACHS & CO. LLCSCHEDULE 13G/A · passive (13G) · 2.3M shares2.0%
    Aug 14, 2025 · ↗
  • THE GOLDMAN SACHS GROUP, INC.SCHEDULE 13G/A · passive (13G) · 2.3M shares2.0%
    Aug 14, 2025 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming FATE THERAPEUTICS INC as client

No lobbying filings found naming FATE THERAPEUTICS INC as the client.

Government Contracts

Federal awards to FATE THERAPEUTICS INC · USAspending

No federal contract awards found for FATE THERAPEUTICS INC.

U.S. Patents

Recent USPTO applications naming FATE THERAPEUTICS INC

No USPTO patent applications found for FATE THERAPEUTICS INC.

Annual Financials

From FATE's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$6.6M$13.6M$63.5M$96.3M$55.8M
Operating income-$147.7M-$210.3M-$190.5M-$308.4M-$217.0M
Net income-$136.3M-$186.3M-$160.9M-$281.7M-$212.2M
Diluted EPS-$1.15-$1.64-$1.64-$2.91-$2.24
Operating cash flow-$106.1M-$122.9M-$132.3M-$248.2M-$162.9M
Cash and equivalents$46.6M$36.1M$41.9M$61.3M$133.6M
Total assets$318.9M$440.7M$506.2M$705.6M$921.5M
Shareholders' equity$207.2M$318.7M$368.4M$483.9M$678.8M

As FATE THERAPEUTICS INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in FATE's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 1.01, 1.02, 9.01Material agreement · Termination of agreementNov 5, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 28, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 13, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 15, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 13, 2026
    EDGAR ↗

About FATE THERAPEUTICS INC

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA